Hello SoundMind Community!

With Oregon and Colorado paving the way for state-level laws that support legal access to psychedelics, we’re now seeing many other states slowly exploring the possibility of expanding access as well. And on that note, we have exciting news to share! 

Recently, our director, Dr. Hannah McLane, had a discussion with Assemblyman Craig J. Coughlin of New Jersey to explore Bill A3852. This bill is known as the "Psilocybin Behavioral Health Access and Services Act,” which aims to authorize the production and use of psilocybin for health and wellness purposes. This is a big deal! 

Dr. Hannah McLane: A Pioneer in Psychedelic Therapy

For those unfamiliar, Dr. Hannah McLane is a physician and psychoanalyst, and also runs one of the nation’s premier psilocybin facilitator training programs. With an educational background from Brown Medical School and Harvard School of Public Health, Dr. Hannah has been leading the charge in innovative mental health treatments at her Philadelphia clinic since 2019, initially with ketamine-assisted psychotherapy. Her extensive training in neurology, occupational medicine, and patient safety perfectly positions her to advocate for the safe and effective use of psilocybin.

More about Bill A3852 

Bill A3852 would allow New Jersey to regulate the production and use of psilocybin to promote health and wellness. The bill establishes a framework for the controlled and supervised administration of psilocybin by licensed facilitators in designated health facilities. This structure includes comprehensive health screenings for potential participants and mandates the presence of qualified practitioners during administration sessions to ensure safety and efficacy. The bill also carries over social equity concepts that were passed in New Jersey’s cannabis legalization, where licensing and services are available at discounted rates to residents of lower earning ZIP codes. 

The legislation highlights the potential therapeutic benefits of psilocybin. It emphasizes the importance of rigorous training and certification for facilitators to maintain high standards of care. Additionally, the bill outlines the process for the legal production of psilocybin, ensuring that it meets stringent safety and quality standards. By implementing these measures, the bill seeks to provide a legal and safe pathway for individuals to access psilocybin therapy.

Addressing the Mental Health Crisis

During her conversation with Assembly Speaker Coughlin, Dr. Hannah highlighted the urgent need for new tools to combat the mental health crisis we face, including rising rates of depression, anxiety, substance abuse, PTSD, and end-of-life anxiety. Traditional treatments often fall short, leaving many without effective options. Enter psilocybin—a naturally occurring psychedelic compound showing great promise in clinical studies.

The Case for Psilocybin

1. Efficacy and Safety: Psilocybin, when administered in a controlled setting by trained facilitators, has shown to be more effective than traditional antidepressants. It’s not about opening dispensaries, but providing guided sessions where clients receive the support they need. The FDA has even given psilocybin a breakthrough therapy designation for major depressive disorder.

2. Comparative Studies: A study published in the New England Journal of Medicine found that psilocybin resulted in remission for 57% of patients with depression, compared to just 28% with traditional antidepressants like Lexapro (Carhartt-Harris et al.). This highlights psilocybin's potential to offer relief where conventional medications may not.

3. Broader Benefits: Beyond depression, psilocybin has shown promise in treating alcoholism, treatment-resistant depression, cluster headaches, and even dementia disorders. A single session can produce significant reductions in symptoms, with many patients experiencing long-lasting benefits.

4. Substance Use Disorders: Research in JAMA Psychiatry demonstrated that a two-session psilocybin treatment was over three times as effective as a placebo in reducing heavy drinking days over a 32-week period (Bogenschutz et al.). This underscores psilocybin’s potential in treating substance use disorders.

The Future of Psilocybin Therapy

Dr. Hannah emphasized the importance of proper health screenings, quality education for facilitators, and setting up accountability systems for effective therapy. Psilocybin's safety profile is impressive, with fewer social and physical harms than substances like alcohol, tobacco, or cannabis. It has low addiction potential and few physical contraindications, making it a viable option for many.

Moving Forward

The discussion between Dr. Hannah and Speaker Coughlin is a promising step towards broader acceptance and legalization of psilocybin therapy. As we continue to educate and train facilitators at SoundMind, we look forward to a future where these therapies can help more people find relief and healing.

Stay tuned for more updates, and thank you for being part of the SoundMind community!

Warm regards,

The SoundMind Team

—---

Check out this link for more details on Bill A3852